RT
RetinalGenix Technologies Inc.
RTGN · OTC
$3.99 +0.00% (+$0.00)
1M +0.00%
Market Cap $75.4M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$2.43
39.1% downside
Current Price
$3.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RTGN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive EV/EBITDA 116.47x
P/S N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 6,487.05%
Asset turnover 0.00x
ROIC 3.00%
Debt
79 /100
Low Int. coverage 89.14x
Net debt/EBITDA 0.04x
Current ratio 0.01x
Stability
19 /100
Unstable EPS volatility 86.03%
Profitable years 0
Beta -3.32x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RTGN
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Jerry Katzman
Employees
0
Headquarters
Apollo Beach